8-K

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

___________

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported) September 2, 2016

VARIAN MEDICAL SYSTEMS, INC.

(Exact Name of Registrant as Specified in its Charter)

Delaware	1-7598	94-2359345
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer  Identification No.)

3100 Hansen Way, Palo Alto, CA	94304-1030
(Address of Principal Executive Offices)	(Zip Code)

Registrant's telephone number, including area code (650) 493-4000

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 1.01. Entry Into a Material Definitive Agreement.

On September 2, 2016, Varian Medical Systems, Inc. (the “Company”) entered into an amendment to its Credit Agreement, dated as of August 27, 2013 (the “Credit Agreement”), by and among the Company and certain lenders party thereto from time to time (collectively, the “Lenders”), and Bank of America, N.A. (“BofA”), as a Lender, Swing Line Lender and L/C Issuer (as such terms are defined in the Credit Agreement) and as administrative agent for the Lenders (the “Agent”).  The amendment, which became effective on September 2, 2016, provides for the consent by the Agent and the Lenders to the Company’s proposed spin off of the Company’s Imaging Components business as more fully described in the Form 10 registration statement filed by Varex Imaging Corporation with the Securities and Exchange Commission on August 11, 2016. 

Item 8.01. Other Events. 

On September 7, 2016, the Company issued a press release entitled “Varian Medical Systems Acquires Distributor in Poland.” A copy of the press release is attached as Exhibit 99.1 and incorporated by reference into this item.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

99.1     Press Release dated September 7, 2016 entitled “Varian Medical Systems Acquires Distributor in Poland.”

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Varian Medical Systems, Inc.
By:	/s/ John W. Kuo
Name:	John W. Kuo
Title:	Senior Vice President, General Counsel and Corporate Secretary

Dated: September 7, 2016

EX-99.1

Exhibit 99.1

Press Contact   Neil Madle Varian Medical Systems +44 7786 526068 neil.madle@varian.com  

FOR IMMEDIATE RELEASE

Varian Medical Systems Acquires Distributor in Poland

Palo Alto, CA., September 7, 2016 – Varian Medical Systems (NYSE:VAR) is announcing the acquisition of the radiotherapy business of Candela, a leading distributor of radiotherapy equipment in Poland. Warsaw-based Candela, which employs more than 40 people, has represented Varian in Poland for the past 20 years. The acquisition closed yesterday following approval from the Polish Competition Authority.

“By bringing Candela’s radiotherapy business into the Varian family we hope to serve our Polish customers even more effectively and continue to improve access to advanced care for cancer patients in the country,” said Jean-Luc Devleeschauwer, president of Varian’s Oncology Systems business in EMEIA. “Candela’s radiotherapy business has an experienced team with strong customer relationships and we were keen to bring this local expertise into Varian.”

“This acquisition strengthens Varian’s position in Poland at a time when both the public and private sectors are investing in modern radiotherapy and radiosurgery equipment to equip the country’s hospitals,” added Aleksander Naumann, CEO of Candela, who will become managing director of Varian Medical Systems Poland. “Varian’s global network and experience will allow us to better serve Polish patients and contribute to Poland’s ability to tackle the scourge of cancer with cost effective, state-of-the-art solutions.”

There are more than 80 Varian medical linear accelerators installed in Polish radiotherapy departments.

# # #

About Varian Medical Systems
Varian Medical Systems, Inc., of Palo Alto, California, focuses energy on saving lives by equipping the world with advanced technology for fighting cancer and for X-ray imaging.  The company is the world's leading manufacturer of medical devices and software for treating cancer and other medical conditions with radiation. The company provides comprehensive solutions for radiotherapy, radiosurgery, proton therapy and brachytherapy. The company supplies informatics software for managing comprehensive cancer clinics, radiotherapy centers and medical oncology practices. Varian is also a premier supplier of X-ray imaging components, including tubes, digital detectors, cables and connectors as well as image processing software and workstations for use in medical and industrial settings, as well as for security and non-destructive testing.  Varian Medical Systems employs approximately 7,700 people who are located at manufacturing sites in North America, Europe, and China and sales and support offices around the world.  For more information, visit http://www.varian.com or follow us on Twitter.

Forward-Looking Statements
Except for historical information, this news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements concerning industry and market outlook, including customer demand and acceptance of products or technology; growth drivers; Varian's future orders, revenues or other financial performance; the ability of Varian’s technology and products to treat cancer; and any statements using the terms “will,” “can,” “future,” “plan,” “expect,” “hope” or similar statements are forward-looking statements that involve risks and uncertainties that could cause the Varian’s actual results to differ materially from those anticipated. Such risks and uncertainties include the ability to effectively integrate the operations of Candela’s radiotherapy business into Varian’s product offerings and sales, marketing and other operations; the ability to retain the services of key Candela personnel; demand for Varian's products and demand for the services of Candela’s radiotherapy business; Varian's ability to develop, commercialize, and deploy new products; the impact of competitive products and pricing; the effect of global economic conditions; Varian’s ability to meet legal and regulatory requirements; changes in the legal or regulatory environment; and the other risks listed from time to time in Varian’s filings with the Securities and Exchange Commission, which by this reference are incorporated herein. Varian assumes no obligation to update or revise the forward-looking statements in this release because of new information, future events, or otherwise.